Bryan Davis, DO
Endocrinology, Diabetes & Metabolism · Sewell, NJNPI 1639425754
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,100 of the $86,423 with a category attached, or 80.0%. 40 manufacturers reported payments, led by Lilly USA, LLC at 53.9% of the total. Reporting peaked in 2024 at $22,272 and has fallen 60.3% since, to $8,852 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 646 payments — averaging $133.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$47K
- AstraZeneca$31K
- Novo Nordisk$2K
- Abbott$921
- Medtronic$726
- Amneal Pharmaceuticals LLC$717
- plus $5K from 34 others
What the payments were for
- Speaking & faculty fees$69,10080%
- Travel & lodging$4,9456%
- Food & beverage$12,11614%
- Education$2030%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 131 | $46,551 |
| AstraZeneca | 89 | $31,158 |
| Novo Nordisk | 97 | $1,547 |
| Abbott | 56 | $921 |
| Medtronic(2 entities) | 6 | $726 |
| Amneal Pharmaceuticals LLC | 44 | $717 |
| Boehringer Ingelheim | 21 | $465 |
| Corcept Therapeutics | 28 | $454 |
| Bayer | 10 | $336 |
| Amgen(2 entities) | 22 | $327 |
| Sanofi-aventis U.S. LLC | 9 | $293 |
| Recordati_rare_diseases_inc. | 18 | $271 |
| Insulet Corporation | 14 | $262 |
| Mannkind Corporation | 5 | $236 |
| Xeris Pharmaceuticals, Inc. | 12 | $229 |
| Tandem Diabetes Care, Inc. | 8 | $227 |
| Radius Health, Inc. | 13 | $222 |
| Zealand Pharma US, Inc. | 6 | $201 |
| Valeritas, Inc. | 1 | $143 |
| IBSA Pharma Inc. | 7 | $109 |
| Ascensia Diabetes Care US Inc. | 6 | $102 |
| Ascendis Pharma Endocrinology Inc | 5 | $89 |
| Madrigal Pharmaceuticals | 4 | $87 |
| Companion Medical, Inc. | 1 | $86 |
| BD | 1 | $78 |
| Tolmar, Inc. | 5 | $74 |
| Kyowa Kirin, Inc. | 4 | $64 |
| Dexcom, Inc. | 2 | $61 |
| RGH Enterprises LLC | 1 | $50 |
| Sequel Med Tech, LLC | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Antares Pharma, Inc. | 2 | $41 |
| AbbVie | 3 | $40 |
| Pfizer | 3 | $40 |
| Cequr Corporation | 1 | $33 |
| Verity Pharmaceuticals Inc. | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Lifescan, Inc. | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$41,837
- FARXIGA$29,748
- MINIMED 780G$272
- INPEN SMART INSULIN DELIVERY SYSTEM$184
- V-GO$143
- Minimed 630G$137
- FreeStyle Libre 2$129
- RYBELSUS$125
- Kerendia$125
- Minimed 670G System$121
- V-GO DISPOSABLE INSULIN DELIVERY$115
- Ozempic$110
- JARDIANCE$105
- AFREZZA$100
How this compares
$86,423 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 609 | $1,264,810 |
| JardianceEmpagliflozin | 417 | $530,611 |
| MounjaroTirzepatide | 320 | $437,496 |
| TrulicityDulaglutide | 187 | $308,013 |
| FarxigaDapagliflozin Propanediol | 213 | $295,532 |
| KorlymMifepristone | 13 | $262,210 |
| RybelsusSemaglutide | 49 | $112,860 |
| TymlosAbaloparatide | 29 | $110,437 |
| Tresiba Flextouch U-200Insulin Degludec | 95 | $95,756 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 63 | $86,311 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $62,401 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $59,857 |
| TradjentaLinagliptin | 36 | $42,126 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $32,532 |
| LyumjevInsulin Lispro-Aabc | 21 | $29,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,547 | $1,397,877672 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Baqsimi | $46,551 | $805,398589 claims |
| Boehringer IngelheimJardiance, Tradjenta | $465 | $572,737453 claims |
| AstraZenecaFarxiga | $31,158 | $295,532213 claims |
| Corcept TherapeuticsKorlym | $454 | $262,21013 claims |
| Radius Health, Inc.Tymlos | $222 | $110,43729 claims |
| Antares Pharma, Inc.Xyosted | $41 | $20,07812 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $293 | $15,91721 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $717 | $8,376515 claims |
| AbbVieSynthroid | $40 | $7,14273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Sewell
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.